Brief Online Mindfulness Training Does Not Reduce Cannabis Use in Adults with Cannabis Use Disorder

A pre-registered, double-blind randomised controlled trial with both active and passive comparators finds no significant benefit of a brief, self-administered online mindfulness-based intervention on cannabis use frequency, quantity, or craving in adults with moderate-to-severe cannabis use disorder.

Why This Matters

Cannabis use disorder affects tens of millions of people worldwide, yet fewer than 15 percent ever seek formal treatment, creating urgent demand for scalable, low-cost interventions that could reach people outside clinical settings. Mindfulness-based interventions have shown promise for other substance use disorders, and brief digital formats represent one of the most plausible paths to population-level impact. This trial arrives at a moment of considerable enthusiasm for app-based and online mental health tools, making its null findings directly relevant to both clinical decision-making and digital health investment.

Clinical Summary

Cannabis use disorder remains among the most undertreated substance use conditions globally, and the limited availability of pharmacological options has driven interest in psychosocial and behavioral alternatives. Mindfulness-based interventions have a plausible mechanistic basis for addressing addiction: they target attentional control, emotion regulation, and reactivity to craving cues, all of which are implicated in the maintenance of compulsive cannabis use. This pre-registered, double-blind, three-arm randomised controlled trial, conducted in Melbourne, Australia, tested whether a brief, self-administered online mindfulness program averaging approximately 16 days could reduce cannabis use in 66 community-recruited adults with moderate-to-severe cannabis use disorder. The study was nested within a larger neuroimaging protocol and included both an active relaxation control and a passive daily-monitoring control.

Across all pre-specified primary and secondary outcomes, no significant intervention-by-time effects were detected after false discovery rate correction. The primary outcome of cannabis use frequency showed no meaningful difference between groups (F=0.26, FDR-corrected p=0.86), and similarly null results were observed for cannabis quantity, craving, mindfulness scores, and relaxation. The authors acknowledge that the small per-arm sample size of approximately 21 to 23 participants likely left the trial underpowered to detect modest but potentially clinically meaningful effects. Equally important, the brevity and self-directed online format of the intervention differ substantially from standard multi-session, clinician-guided mindfulness programs that have shown efficacy in other substance use populations. The authors emphasize that larger, better-powered trials testing more intensive mindfulness formats are needed before clinical conclusions about the broader class of mindfulness-based interventions for cannabis use disorder can be drawn.

Dr. Caplan’s Take

This study does something genuinely valuable: it tests a popular idea with the right controls and reports the null result honestly. The three-arm design with both active and passive comparators is better than what we see in most mindfulness research, and the pre-registration adds credibility. But the intervention tested here, roughly two weeks of self-guided online mindfulness, is a long way from what we would consider a therapeutic dose. Patients frequently ask me whether meditation or a mindfulness app might help them cut back on cannabis, and this study is a useful anchor for an honest conversation: we do not yet have evidence that a brief digital tool, used alone, will move the needle on established cannabis use disorder.

In practice, I treat mindfulness skills as a potentially useful component of a broader treatment plan rather than a standalone intervention for cannabis use disorder. When patients are motivated and curious about mindfulness, I encourage longer-duration, structured programs, ideally with clinician involvement, and I frame them as complementary to other evidence-based approaches. I do not discourage interest in mindfulness, but I am direct about the gap between what apps promise and what the current evidence supports for this specific condition.

Clinical Perspective

This trial sits early in the research arc for digital mindfulness interventions targeting cannabis use disorder specifically. While mindfulness-based relapse prevention has accumulated moderate evidence for alcohol and mixed substance use populations, translation to cannabis use disorder has been limited and this study does not advance the case. The consistent null findings across all outcomes, including the mechanistic targets of mindfulness and craving, suggest that the intervention as delivered did not engage its intended therapeutic pathways. However, the study cannot tell us whether the problem is mindfulness itself, the dose, the delivery format, or the population. Clinicians should avoid interpreting this as evidence that mindfulness-based interventions broadly do not work for cannabis use disorder, while also recognizing that no brief digital tool currently has robust support for this indication.

There are no significant pharmacological safety concerns with a self-guided mindfulness intervention per se, though clinicians should remain attentive to the possibility that patients pursuing digital-only interventions may delay engagement with more effective treatments. The self-monitoring component used across all three trial arms, in which participants tracked daily cannabis use, itself represents a potentially active therapeutic element. One actionable recommendation: when patients with cannabis use disorder express interest in mindfulness-based approaches, clinicians should steer them toward longer-duration, evidence-informed programs with some degree of professional guidance, and position these within a comprehensive treatment plan that includes motivational enhancement or cognitive behavioral strategies with established efficacy for this population.

Study at a Glance

Study Type

Pre-registered, double-blind, three-arm randomised controlled trial

Population

66 adults aged 18 to 56 with moderate-to-severe cannabis use disorder, community-recruited in Melbourne, Australia

Intervention

Brief self-administered online mindfulness-based intervention, mean duration approximately 16 days

Comparator

Active control (brief online relaxation training) and passive control (daily cannabis use monitoring only)

Primary Outcomes

Change in cannabis use days from baseline to follow-up

Sample Size

66 participants (approximately 21 to 23 per arm)

Journal

Not specified in available metadata

Year

Recruitment October 2019 to July 2022; publication year not specified

DOI or PMID

Trial registration: ISRCTN76056942; OSF pre-registration: osf.io/sfjwk

Funding Source

Not specified in available metadata

What Kind of Evidence Is This

This is an original, pre-registered, double-blind randomised controlled trial reporting primary data from 66 adults with cannabis use disorder. As a prospective RCT with allocation concealment, stratified randomization, and intention-to-treat analysis, it occupies a relatively strong position in the evidence hierarchy for evaluating intervention efficacy. The most important inference constraint is the small per-arm sample size of approximately 21 to 23 participants, which limits statistical power and makes it difficult to distinguish a true null effect from an underpowered negative result, leaving effect size estimates imprecise.

How This Fits With the Broader Literature

Mindfulness-based relapse prevention has shown modest efficacy for alcohol and mixed substance use populations in trials such as the Bowen et al. (2014) multi-site RCT, but evidence specific to cannabis use disorder has been sparse and largely limited to pilot studies. The present trial’s null findings are consistent with a broader pattern in digital mental health research suggesting that very brief, self-administered interventions tend to produce smaller and less reliable effects than clinician-guided programs of standard therapeutic duration. The results do not contradict the mechanistic rationale for mindfulness in addiction, which centers on disrupting habitual craving responses through improved attentional control, but they do underscore that dose and delivery context likely matter substantially.

Importantly, this trial’s inclusion of an active relaxation control helps isolate the specific contribution of mindfulness above general relaxation, a design element absent from many prior studies. The finding that relaxation training also produced no benefit relative to passive monitoring suggests that the issue may lie with intervention intensity rather than the mindfulness component specifically.

Common Misreadings

The most likely overinterpretation is concluding that mindfulness-based interventions do not work for cannabis use disorder. This trial tested one specific format: a brief, self-administered, online-only program lasting roughly two weeks, which bears limited resemblance to evidence-based mindfulness programs that typically involve eight or more weekly sessions with clinician facilitation. The null result is informative about this particular delivery model and dose, but it cannot speak to the efficacy of more intensive mindfulness programs. Equally, the small sample size means that modest but potentially meaningful effects could have gone undetected, so framing this as a definitive negative trial would overstate what the data support.

Bottom Line

This well-controlled but small trial found no evidence that a brief, self-administered online mindfulness intervention reduces cannabis use, quantity, or craving in adults with cannabis use disorder. The null findings temper enthusiasm for ultra-brief digital mindfulness tools as standalone treatments for this condition but do not rule out benefits from more intensive, clinician-guided mindfulness programs. For now, clinicians should not recommend brief digital mindfulness interventions as primary treatment for cannabis use disorder and should await larger trials testing programs of adequate therapeutic dose.

References

1. Trial registration: ISRCTN76056942. Available at: https://www.isrctn.com/ISRCTN76056942
2. Pre-registration protocol: Open Science Framework. Available at: https://osf.io/sfjwk
3. Bowen S, Witkiewitz K, Clifasefi SL, et al. Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders: a randomized clinical trial. JAMA Psychiatry. 2014;71(5):547-556. doi:10.1001/jamapsychiatry.2013.4546